Literature DB >> 26622379

Improvement of liver function by the administration of oyster extract as a dietary supplement to habitual alcohol drinkers: A pilot study.

Kenji Osaki1, Yoshio Shimizu2, Tetsuro Yamamoto3, Fumiharu Miyake4, Sumio Kondo5, Hideyo Yamaguchi3.   

Abstract

Alcoholic liver disease (ALD) is characterized by elevated serum γ-glutamyltransferase (GGT) activity with hepatic steatosis, hepatitis or occasionally fibrosis that may progress to cirrhosis. The potential therapeutic role of oyster extract (OE) or OE-containing dietary supplements (OE supplement) in ALD has seldom been evaluated. In the present study, 84 adults who had an alcohol-drinking habit and marginally high serum GGT levels were enrolled in a randomized, double-blind, placebo-controlled feeding trial to study the effect on alcohol-impaired liver function as reflected by an increased serum level of GGT, as well as the safety, of an OE supplement. The subjects were randomized to receive either an OE supplement (OE group) or placebo (placebo group). There were 42 subjects (31 males and 11 females) in each group, and all the enrolled subjects entered the study. Four individuals (5%) dropped out for reasons unassociated with the study and 6 other subjects were excluded from the efficacy analysis because they did not maintain the required frequency of alcohol intake. As a result, 38 subjects in the placebo group and 36 in the OE group underwent efficacy assessment. Assays of GGT and other liver enzymes were performed at baseline (week 0) and at weeks 4, 8 and 12 of the intervention period. The mean serum levels of GGT in the placebo group gradually increased, while those in the OE group tended to decrease, although no significant within-group differences were observed for either group. A significant between-group difference in the change of mean GGT from baseline was, however, found at week 12 (P=0.049). No OE supplement-associated untoward side-effects nor any abnormal changes in routine laboratory tests and anthropometric parameters were observed throughout the 12-week intervention. An OE supplement shows promise in reducing risk factors associated with ALD in adults with an alcohol intake habit.

Entities:  

Keywords:  feeding trial; habitual alcohol drinking; liver function; oyster extract; taurine; γ-glutamyltransferase

Year:  2015        PMID: 26622379      PMCID: PMC4509380          DOI: 10.3892/etm.2015.2563

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  31 in total

1.  [Epidemiology of alcohol and liver disease].

Authors:  Xiaolan Lu; Ming Tao; Jinyan Luo; Yan Geng; Hongli Zhao; Ping Zhao
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2002-12

Review 2.  Alcoholic hepatitis.

Authors:  Michael R Lucey; Philippe Mathurin; Timothy R Morgan
Journal:  N Engl J Med       Date:  2009-06-25       Impact factor: 91.245

3.  The burden of alcohol misuse on an inner-city general hospital.

Authors:  M Pirmohamed; C Brown; L Owens; C Luke; I T Gilmore; A M Breckenridge; B K Park
Journal:  QJM       Date:  2000-05

4.  Regression of liver fibrosis by taurine in rats fed alcohol: effects on collagen accumulation, selected cytokines and stellate cell activation.

Authors:  Shanmugam Lakshmi Devi; Periyaswamy Viswanathan; Carani V Anuradha
Journal:  Eur J Pharmacol       Date:  2010-09-04       Impact factor: 4.432

5.  Taurine supplementation prevents ethanol-induced decrease in serum adiponectin and reduces hepatic steatosis in rats.

Authors:  Xiaocong Chen; Becky M Sebastian; Hui Tang; Megan M McMullen; Armend Axhemi; Donald W Jacobsen; Laura E Nagy
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

Review 6.  Recent developments in the treatment of alcoholic hepatitis.

Authors:  R Madhotra; I T Gilmore
Journal:  QJM       Date:  2003-06

7.  Taurine: protective properties against ethanol-induced hepatic steatosis and lipid peroxidation during chronic ethanol consumption in rats.

Authors:  M D Kerai; C J Waterfield; S H Kenyon; D S Asker; J A Timbrell
Journal:  Amino Acids       Date:  1998       Impact factor: 3.520

Review 8.  Treatment of alcoholic liver disease.

Authors:  Ashutosh Barve; Rehan Khan; Luis Marsano; Kadiyala V Ravindra; Craig McClain
Journal:  Ann Hepatol       Date:  2008 Jan-Mar       Impact factor: 2.400

9.  Differential responses of serum gamma-glutamyltransferase to alcohol intake in Japanese males.

Authors:  Yoko Matsuka; Da-Hong Wang; Narufumi Suganuma; Kaori Imai; Satoru Ikeda; Kazuhisa Taketa; Shohei Kira
Journal:  Acta Med Okayama       Date:  2003-08       Impact factor: 0.892

10.  Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: results from a multisite study.

Authors:  Raymond F Anton; Charles Lieber; Boris Tabakoff
Journal:  Alcohol Clin Exp Res       Date:  2002-08       Impact factor: 3.455

View more
  3 in total

1.  miR‑148a‑3p regulates alcoholic liver fibrosis through targeting ERBB3.

Authors:  Jie Xiong; Jianbo Ni; Congying Chen; Kezhou Wang
Journal:  Int J Mol Med       Date:  2020-06-23       Impact factor: 4.101

2.  Hepatoprotective Effect of Oyster Peptide on Alcohol-Induced Liver Disease in Mice.

Authors:  Xueqin Wang; Huahua Yu; Ronge Xing; Pengcheng Li
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

3.  Dipeptide YA is Responsible for the Positive Effect of Oyster Hydrolysates on Alcohol Metabolism in Single Ethanol Binge Rodent Models.

Authors:  Adrian S Siregar; Marie Merci Nyiramana; Eun-Jin Kim; Eui-Jung Shin; Min Seok Woo; Jin-Mok Kim; Jung Hwan Kim; Dong Kun Lee; Jong Ryeal Hahm; Hyun Joon Kim; Chang-Woon Kim; Nam-Gil Kim; Si-Hyang Park; Yeung Joon Choi; Sang Soo Kang; Seong-Geun Hong; Jaehee Han; Dawon Kang
Journal:  Mar Drugs       Date:  2020-10-11       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.